Back to search

Peptide record

TPDB09812

PTD11 (TP10) TP10-anti-gyrA PNA/scPNA Transportan transportan (TP)10 TP10 Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09812
PTD11 (TP10) TP10-anti-gyrA PNA/scPNA Transportan transportan (TP)10 TP10
Antibacterial Anticancer Antifungal Antiparasitic Blood-Brain Barrier Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP Peptipedia Antifungipept CAFPdb dbAMP 3.0 i2APP B3Pred BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
AGYLLGKINLKALAALAKKIL
Physicochemical Analysis
C104H184N26O24
RDCEQHMFPSTWV
L
2182.76
10.64
4
0
14
+4
-1.37
0.933
172.38
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
68.26
2
Residue Composition
number
5
A
0
R
1
N
0
D
0
C
0
E
0
Q
2
G
0
H
2
I
6
L
4
K
0
M
0
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 5 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 2 L: 6 K: 4 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
21
C104H184N26O24
2182.76
10.64
+4
-1.37
0.933
Free
L
Cationic
Linear
Free
NCC(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1[nH]cnc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=NC=NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CC(=O)OOC(=O)[C@H]2N(C1=O)CCC2 N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)O N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O
Evidence Records 19 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

S. Aureus Infected Mac-T Or Hbmec Cell Lines , Ex Vivo Calvaria (Skull Cap)

Assay & Model

Femur injury model (Wistar rats (5 to 6 wks of age))
Femur injury model (Wistar rats (5 to 6 wks of age))

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L
Synthetic
Lysostaphin and LysK
In vitro and in vivo
CCCCCCSSCCSCCSCHHHHHHTGGGCC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

Dc2.4 Dcs , Splenocytes From C57Bl/6 Mice

Assay & Model

C57BL/6 mice
C57BL/6 mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
FITC-dye and gp100 peptide to the N terminus
Cytosol
Endocytosis
In vitro and in vivo
CCSSCGGGHHHHSCCC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

S. Pyogenes Strains

Assay & Model

G. mellonella Larvae
G. mellonella Larvae

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
Protein derived
anti-gyrA antisense PNAs and scrambled PNAs [scPNAs]
In vitro and in vivo
CGGGTTTTSSCC
Evidence 4 Activity

Activity

Cell-penetrating Peptides

Assay & Model

P. falciparum trophozoite stage cells
P. falciparum trophozoite stage cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
SYBR green-I, doxorubicin and actinomycin D
In vivo
CCCCCCCC
Evidence 5 Activity

Activity

Cell-penetrating Peptides

Target

Nih/3T3, CHO-K1, Or HeLa Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L
TfAF488 or 0.2-μm microspheres , lentivirus particles carrying the pac gene
PepB2 show greater efficacy than other
In vitro
CCSSSCTTSSCCCSSSCC
Evidence 6 Activity

Activity

Cell-penetrating Peptides

Target

Monomac6 Human Monocytes

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
Cellular uptake slightly affected by CF-labelling
In vitro
CCCSSSTTCCCTTTTC
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

HeLa pLuc705 cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Non-natural residues Linear L
Synthetic
SR-A3s and SR-A5s
Cytoplasm
In vitro
Evidence 8 Activity

Activity

IC50
Toxicity
12.00±0.93 µM
Cytotoxic
IC50 | 12.00±0.93 | µM | target cell: Human foreskin fibroblasts Hs27

Target

Human foreskin fibroblasts Hs27

Source & Reference

NA
DBAASP
New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets. | Pharmaceutics | 2024
Evidence 9 Activity

Activity

IC90
Toxicity
28.81±0.87 µM
Cytotoxic
IC90 | 28.81±0.87 | µM | target cell: Human foreskin fibroblasts Hs27

Target

Human foreskin fibroblasts Hs27

Source & Reference

NA
DBAASP
New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets. | Pharmaceutics | 2024
Evidence 10 Activity

Activity

IC50
Toxicity
14.45±1.13 µM
Cytotoxic
IC50 | 14.45±1.13 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets. | Pharmaceutics | 2024
Evidence 11 Activity

Activity

IC90
Toxicity
34.30±1.00 µM
Cytotoxic
IC90 | 34.30±1.00 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets. | Pharmaceutics | 2024
Evidence 12 Activity

Activity

5% Hemolysis
Toxicity
30 µM
Hemolytic Cytotoxic
5% Hemolysis | 30 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. | Antimicrob Agents Chemother | 2008
Evidence 13 Activity

Activity

0% Hemolysis
Toxicity
2 µM
Hemolytic Cytotoxic
0% Hemolysis | 2 | µM | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. | FASEB J | 2004
Evidence 14 Activity

Activity

2% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
2% Hemolysis | 10 | µM | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. | FASEB J | 2004
Evidence 15 Activity

Activity

4% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
4% Hemolysis | 50 | µM | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. | FASEB J | 2004
Evidence 16 Activity

Activity

12% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
12% Hemolysis | 100 | µM | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. | FASEB J | 2004
Evidence 17 Activity

Activity

80% Hemolysis
Toxicity
512 µg/mL
Hemolytic Cytotoxic
80% Hemolysis | 512 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial activities and action mechanism studies of transportan 10 and its analogues against multidrug-resistant bacteria. | J Pept Sci | 2015
Evidence 18 Activity

Activity

LC
Toxicity
128 µg/mL
Cytotoxic
LC | 128 | µg/mL | target cell: Human umbilical vein endothelial cells HUVEC

Target

Human umbilical vein endothelial cells HUVEC

Source & Reference

NA
DBAASP
Antimicrobial activities and action mechanism studies of transportan 10 and its analogues against multidrug-resistant bacteria. | J Pept Sci | 2015
Evidence 19 Hemolysis

Source & Reference

HemoPI PD_Hemolysis
PD_Hemolysis
Additional Detail Fields 1 fields
CCCCCCSSCCSCCSCHHHHHHTGGGCC CCSSCGGGHHHHSCCC CGGGTTTTSSCC CCCCCCCC CCSSSCTTSSCCCSSSCC CCCSSSTTCCCTTTTC